MeiraGTx Holdings plc (MGTX) saw its shares decline 5.5% on Friday, closing at $9.40, which capped a 4.3% weekly loss after a late-week selloff. The stock's pullback erased recent gains driven by pipeline updates and financing news, leaving investors focused on the company's transition from a research-stage biotech to a regulatory-driven story.
Q1 Results and Cash Position
The company reported a first-quarter net loss of $46.3 million, or 57 cents per share, widening from a loss of $40.0 million a year earlier. Service revenue dropped sharply to $293,000 from $1.9 million in the prior-year period. As of March 31, MeiraGTx held $71.5 million in cash and cash equivalents, with an accumulated deficit of $862.5 million. The company's cash runway was extended by an April equity offering that raised approximately $100 million through the sale of 11.1 million ordinary shares at $9.00 each, though the move diluted existing shareholders.
Regulatory Milestones and Pipeline Progress
MeiraGTx announced it received FDA Breakthrough Therapy Designation for AAV2-hAQP1, a potential treatment for hard-to-treat diseases, which could expedite regulatory discussions. The company is also advancing bota-vec (botaretigene sparoparvovec) toward regulatory filings in the U.S., Europe, the U.K., and Japan. Bota-vec targets X-linked retinitis pigmentosa, a rare inherited eye disorder that leads to vision loss. In April, MeiraGTx agreed to repurchase bota-vec from Johnson & Johnson for $25 million upfront, with additional potential milestones tied to regulatory, commercial, and royalty payments.
Analyst Sentiment and Market Context
RBC Capital Markets maintained its bullish rating on MeiraGTx and raised its price target to $25 from $24, according to MT Newswires via MarketScreener. However, the stock's current price of $9.40 remains well below that target. The gene therapy sector remains in focus, with peers like Rocket Pharmaceuticals progressing cardiovascular gene therapy and gaining approval for KRESLADI, while 4D Molecular Therapeutics advances a late-stage retina gene therapy for wet age-related macular degeneration.
Strategic Partnership and Financial Outlook
MeiraGTx secured a major partnership with Eli Lilly in November, which included a $75 million upfront payment and up to $400 million in milestones for rights to a gene therapy targeting a rare inherited eye disorder. The deal's total potential value exceeds $475 million. CEO Alexandria Forbes stated that early 2026 has materially strengthened the company, positioning it for potential approval and commercial launch of two wholly owned therapies within the next two years. She emphasized the company is working expeditiously on bota-vec regulatory filings.
Risks and Next Catalysts
Despite recent progress, MeiraGTx faces significant risks, including regulatory setbacks, clinical trial failures, and the challenges of gene therapy commercialization, such as manufacturing, reimbursement, and patient access. The company's latest 10-Q filing highlights deep losses, no guarantee of profitability, and the need for additional funding, with cash potentially running out sooner than anticipated. Investors will watch for next steps, as fresh Phase 2 AQUAx2 data for AAV2-hAQP1 is not expected until the second quarter of 2027, and the next bota-vec update will focus on regulatory filings rather than revenue. The stock's Monday open will be closely monitored for signs of whether Friday's decline was a temporary pause or the start of a deeper pullback.
